Clinical trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

NCT04451837

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-09-10

PhasePHASE2

Study timeline

Study start (actual)2020-09-10Date precision: day

Registry last updated2025-07-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type2 Diabetesunresolved

Interventions

SemaglutideDRUG · verified · RxNorm: semaglutide

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

Sponsors & collaborators

Region Skanelead sponsor

Göteborg Universitycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04451837 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.